Merck & Co. Stock Buy or Sell? MRK Stocks Forecast

Market Capitalization: 328 028 881 000 $
EBITDA: 9 983 000 000 $
Price to Earnings: 924.64
Quarterly Earnings Growth YOY: 0.453
Quarterly Revenue Growth YOY: 0.058
Trailing PE: 924.64
Forward PE: 15.13
Shares Outstanding: 2534020000






Buy or Sell AMZN stocks? (AMZN) forecasting

Amazon’s Stock Looks Cheap

February 29, 2024
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Merck & Co. Stock Buy or Sell? MRK Stocks Analytic Forecasts

Updated on March 1, 2024 (09:57)

Merck & Co., Inc. (MRK prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the MRK stock market. Experts share their opinions on what to expect from the Merck & Co., Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Merck & Co. stocks.

Merck & Co., Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy MRK Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Edmund Ingham and is titled

“Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings”

is published on January 29 (2024) and has 0 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • Merck & Co has experienced significant share price growth across the past 3 years, bettered only in the big pharma sector by Eli Lilly and Novo Nordisk.
  • Merck’s >$20bn selling cancer drug Keytruda’s patents are set to expire in 2028, leading to concerns about declining revenues after that year.
  • Merck is focused on developing its pipeline, which includes 8 novel assets undergoing 20 Phase 3 studies, and has invested over $50 billion in M&A since 2019.
  • As such, MRK is well positioned to prepare for a post-keytruda patent expiry world, although the drug will likely substantially grow revenues over the next 3 years.
  • As such, if the market becomes jittery around keytruda, I’d interpret that as a potential buying opportunity. I am expecting a solid set of earnings from the New Jersey Pharma when they are announced this Thursday.

The author starts his analytic review with the following:

Investment Overview Over the past three years, if we ignore the two outliers Eli Lilly (LLY), and Novo Nordisk (NVO) – whose launching of GLP-1 agonist drugs targeting Type 2 diabetes and obesity, Mounjaro / Zepbound, and Ozempic / Wegovy have helped support a >200% rise in their share prices – Merck & Co. (NYSE:MRK), the world’s fourth largest Pharma by market cap valuation – currently $306bn – has been the “best of the rest” in terms of share price growth.

This author is very popular among the auditory. He has 10770 followers

Edmund Ingham is the contributor of experts community since 2018 and has a great number of published articles – 662.


One more noteworthy article is written by Danil Sereda under the title

“Merck: Set To Keep Soaring Post Q4 Release”

on January 29 (2024) and has 11 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add MRK stocks to your investment portfolio or not, and helps to work out your own Merck & Co. stock selling strategies:

  • Merck & Co. is likely to positively surprise the market on February 1, 2024 (estimated Q4 FY2023 release date), according to the findings of my analysis.
  • The company’s Q3 performance exceeded expectations, driven by strong sales in the Oncology and Vaccines businesses, particularly the success of Keytruda.
  • Merck’s strategic collaborations and pipeline developments contribute to a positive outlook, with significant revenue growth expected in the next few years. It might not be priced in yet.
  • I calculate Merck’s equity value at ~$468.91 billion by the end of 2025. This means an upside potential of around 55.7% over the next two years.
  • The implied volatility for MRK is low at its 76th percentile, indicating a potentially favorable setup for upcoming earnings. I rate the stock as a ‘Buy’ right before the Q4 release.

Danil Sereda starts analysis with such words:

Thesis In today’s article, I highlight the latest financials and corporate events of Merck & Co (NYSE:MRK), a global pharmaceutical company with a market cap of $300 billion and a focus on healthcare solutions, which is likely to positively surprise the market on February 1, 2024 (estimated Q4 FY2023 release date), according to the findings of my analysis.

The opinion of the author can be considered quite authoritative.
The number of 8100 followers confirms this.
Danil Sereda is the contributor of experts community since 2020. Has already published at least 422 articles.


Another analysis presented by ALLKA Research came out on January 8 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for MRK stocks. It sounds like

“Merck’s Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls”

Article has got 0 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Merck & Co., Inc., the expert says the following:

  • Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases.
  • On October 26, 2023, Merck published results for the 3rd quarter of 2023, which left mixed feelings.
  • The exclusivity of most of the company’s medications and vaccines is set to expire within the next five years.
  • However, in October, Merck entered into an agreement with Daiichi Sankyo to develop and subsequently commercialize three experimental antibody-drug conjugates for up to $22 billion.
  • I’m initiating coverage of Merck stock with a “hold” rating.

And here, what comes first:

Merck (NYSE:MRK) is an American pharmaceutical company whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases.

The author declares an interesting position, and the number of his followers is 158 and it grows, but not that weighty compared to other authors.
ALLKA Research has 6 analytic reviews published.
The contributor of experts community since 2023


The Share Price of Merck & Co., Inc. (MRK) for now

What analysts predict: $134.18
52-week high/low: $130.24 / $98.43

50/200 Day Moving Average: $118.18 / $110.12

The average stock price over the previous 50/200 days. For Merck & Co. stocks, the 50-day moving average is the resistance level for now. For MRK stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for MRK stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.